Pharmaceutical market access in emerging markets: concepts, components, and future
- PMID: 27226834
- PMCID: PMC4865763
- DOI: 10.3402/jmahp.v2.25302
Pharmaceutical market access in emerging markets: concepts, components, and future
Abstract
This article intends to consolidate the concepts of pharmaceutical market access and highlight its growing importance in emerging markets. Market access has gained considerable attention worldwide as countries try to contain their escalating healthcare expenditures amidst the global economic slowdown. This has resulted in governments adopting stricter measures for new product approval. Thus, pharmaceutical companies are finding it increasingly difficult to successfully address the specific challenges posed by various government and regulatory agencies and stakeholders. There is an increasing need to establish market access functions, especially in emerging markets, where the complex, dynamic healthcare landscape confounds product approval and uptake. Moreover, emerging markets are the engines of growth today, and, thus, performing in these markets is critical for the majority of pharmaceutical companies. To address the challenges posed by regulatory agencies and diverse stakeholders, a customized market access strategy is the need of the hour. A market access framework with specific tools and tactics will help companies to plan, implement, and monitor stakeholder engagement activities.
Keywords: developed markets; emerging markets; escalating healthcare cost; market access framework; pharmaceutical market access; pricing and reimbursement; stakeholders.
Similar articles
-
The Influence of Emerging Markets on the Pharmaceutical Industry.Curr Ther Res Clin Exp. 2017 Apr 18;86:19-22. doi: 10.1016/j.curtheres.2017.04.005. eCollection 2017. Curr Ther Res Clin Exp. 2017. PMID: 29234483 Free PMC article. Review.
-
New drug regulations in France: what are the impacts on market access? Part 2 - impacts on market access and impacts for the pharmaceutical industry.J Mark Access Health Policy. 2013 Aug 6;1. doi: 10.3402/jmahp.v1i0.20892. eCollection 2013. J Mark Access Health Policy. 2013. PMID: 27226829 Free PMC article.
-
Drug lag and key regulatory barriers in the emerging markets.Perspect Clin Res. 2010 Apr;1(2):51-6. Perspect Clin Res. 2010. PMID: 21829782 Free PMC article.
-
Requirements for a Successful Drug Launch in Small Markets: A Pilot Study in Lebanon.Value Health Reg Issues. 2019 Sep;19:59-64. doi: 10.1016/j.vhri.2019.01.006. Epub 2019 May 9. Value Health Reg Issues. 2019. PMID: 31078969
-
New ways of insulin delivery.Int J Clin Pract Suppl. 2011 Feb;(170):31-46. doi: 10.1111/j.1742-1241.2010.02577.x. Int J Clin Pract Suppl. 2011. PMID: 21323811 Review.
Cited by
-
Conceptualisation and Role of Market Access in Pharmaceutical Industry: A Scoping Review.J Mark Access Health Policy. 2024 May 1;12(2):81-99. doi: 10.3390/jmahp12020007. eCollection 2024 Jun. J Mark Access Health Policy. 2024. PMID: 38808312 Free PMC article.
-
Recommendations to conduct and report systematic reviews in medical literature: a scoping review.BMC Med Res Methodol. 2019 Dec 11;19(1):234. doi: 10.1186/s12874-019-0870-1. BMC Med Res Methodol. 2019. PMID: 31829132 Free PMC article.
-
Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settings.J Mark Access Health Policy. 2016 Sep 27;4. doi: 10.3402/jmahp.v4.31660. eCollection 2016. J Mark Access Health Policy. 2016. PMID: 27857827 Free PMC article.
-
Suitability of paediatric legislation beyond the USA and Europe: a qualitative study on access to paediatric medicines.BMJ Public Health. 2024 Feb 7;2(1):e000264. doi: 10.1136/bmjph-2023-000264. eCollection 2024 Jun. BMJ Public Health. 2024. PMID: 40018188 Free PMC article.
-
Understanding medicine access strategies for innovator medicines registered in South Africa.BMC Health Serv Res. 2024 Oct 11;24(1):1220. doi: 10.1186/s12913-024-11696-4. BMC Health Serv Res. 2024. PMID: 39394111 Free PMC article.
References
-
- Lataillade TD, Billy A. Market access in Europe: An exclusive survey on biopharmaceutical industry trends. Cegedim Relationship Management; 2010. Available from: http://crm.cegedim.com/Docs_Whitepaper/Data/EU_Market_Access_Survey_Whit... [cited 14 May 2014]
-
- Hulten EV, Lataillade TD. Market Access in Europe 2011. Cegedim Relationship Management; 2011. Available from: http://crm.cegedim.com/Docs_Whitepaper/Data/EU_Market_Access_Survey_Rpt_... [cited 30 April 2014]
-
- Wang L, Richardson R. Planning for change: Adapting to shifts in the global market access landscape. Campbell Alliance; No date. Available from: http://www.campbellalliance.com/articles/Campbell_Alliance_Global_Market... [cited 14 June 2014]
-
- Mikkelsen JS. Market access for medical technology & pharmaceutical companies: An organizational priority in times of economic austerity and reform. 2012. Available from: http://um.dk/en/~/media/USA/Market Access for Medical Technology Pharmac... [cited 24 April 2014]
-
- Forcellina A, Akannac C. Managing talent to meet pharma's next great challenge: Global market access, 2013. Egon Zehnder International; 2013. Available from: http://www.egonzehnder.com/files/managing_talent_to_meet_pharmas_next_gr... [cited 17 October 2014]
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources